Physician profile
Abigail Stone
NPI 1457003600
$2,556.25
in general payments reported to CMS, 2019-2025
34 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.49 · 2023: $1,206 · 2024: $1,162 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.77 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.54 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.36 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $201.10 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $159.00 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $137.24 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $110.47 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.15 | 2023-2024 | Xifaxan, Trulance |
| Corium, LLC | $103.53 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $99.50 | 2023-2024 | Trelegy Ellipta, Rotarix, Pediarix |
| Organon LLC | $97.59 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $85.82 | 2023-2024 | Belsomra, Steglujan, Steglatro |
| Astellas Pharma US INC | $83.09 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.45 | 2023-2024 | Jardiance |
| Neos Therapeutics, LP | $63.20 | 2023-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $56.20 | 2023-2024 | Vyepti, Rexulti |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.67 | 2023-2024 | Dupixent |
| Optinose US, INC. | $47.86 | 2023-2024 | |
| Pfizer INC. | $46.29 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $46.26 | 2023-2024 | Linzess |
| Amgen INC. | $45.71 | 2023-2024 | Otezla, Repatha |
| Ardelyx, INC. | $35.92 | 2024 | Ibsrela |
| Axsome Therapeutics, INC. | $35.72 | 2023-2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $31.92 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $18.77 | 2024 | Quviviq |
| Alnylam Pharmaceuticals INC. | $17.85 | 2023 | Amvuttra |
| Bausch Health US, LLC | $17.55 | 2023 | Aplenzin |
| Boston Scientific Corporation | $17.49 | 2022 | |
| Tris Pharma INC | $17.44 | 2023 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $17.35 | 2023 | Austedo |
| Supernus Pharmaceuticals, INC. | $16.21 | 2024 | Qelbree |
| Exeltis, USA INC. | $15.47 | 2023 | Slynd |
| Janssen Pharmaceuticals, INC | $14.64 | 2024 | Xarelto |
| Impel Pharmaceuticals INC. | $14.27 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.